Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer
Season 2, Episode 30, May 30, 06:07 PM
Share
Subscribe
Episode Description
This PER® Show Me Your Care Plan!™ featured podcast brings together two medical oncologists and an oncology nurse to discuss the latest advances in the management of platinum-resistant ovarian cancer (PROC). The expert panel reviews current and emerging therapies, with a special focus on the management of adverse events associated with mirvetuximab soravtansine (MIRV) and other novel agents. Designed for oncology nurses and the broader care team, this program provides practical insights for integrating new evidence-based strategies into clinical practice to optimize outcomes for patients with PROC.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AbbVie Inc and Corcept Therapeutics, Incorporated.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Instructions on How to Receive Credit
This PER® Show Me Your Care Plan!™ featured podcast brings together two medical oncologists and an oncology nurse to discuss the latest advances in the management of platinum-resistant ovarian cancer (PROC). The expert panel reviews current and emerging therapies, with a special focus on the management of adverse events associated with mirvetuximab soravtansine (MIRV) and other novel agents. Designed for oncology nurses and the broader care team, this program provides practical insights for integrating new evidence-based strategies into clinical practice to optimize outcomes for patients with PROC.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AbbVie Inc and Corcept Therapeutics, Incorporated.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Instructions on How to Receive Credit
- Listen to this podcast in its entirety.
- Go to gotoper.com/credit and enter code: 6725
- Answer the evaluation questions.
- Request credit using the drop-down menu.
You may immediately download your certificate.
Today's faculty are:
Ritu Salani, MD, MBA
Professor, Department of Obstetrics and Gynecology
Director, Gynecologic Oncology
David Geffen School of Medicine at UCLA
University of California, Los Angeles
Los Angeles, CA
Disclosures: Consultant: Daiichi Sankyo; Advisory Board: AbbVie, Eisai, GSK, Merck, Pfizer, Regeneron
Emely Alfaro, MS, RN, CNS, OCN
Assistant Clinical Professor
UCSF School of Nursing
Clinical Nurse Specialist, Outpatient Adult Oncology
Adult Infusion Services
San Francisco, CA
Disclosures: Emely Alfaro, MS, RN, CNS, OCN, has no relevant financial relationships with ineligible companies.
Jill Alldredge, MD
Assistant Professor
Division of Gynecologic Oncology
University of Colorado
Denver, CO
Disclosures: Jill Alldredge, MD, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date: May 30, 2025
Expiration Date: May 30, 2026
Today's faculty are:
Ritu Salani, MD, MBA
Professor, Department of Obstetrics and Gynecology
Director, Gynecologic Oncology
David Geffen School of Medicine at UCLA
University of California, Los Angeles
Los Angeles, CA
Disclosures: Consultant: Daiichi Sankyo; Advisory Board: AbbVie, Eisai, GSK, Merck, Pfizer, Regeneron
Emely Alfaro, MS, RN, CNS, OCN
Assistant Clinical Professor
UCSF School of Nursing
Clinical Nurse Specialist, Outpatient Adult Oncology
Adult Infusion Services
San Francisco, CA
Disclosures: Emely Alfaro, MS, RN, CNS, OCN, has no relevant financial relationships with ineligible companies.
Jill Alldredge, MD
Assistant Professor
Division of Gynecologic Oncology
University of Colorado
Denver, CO
Disclosures: Jill Alldredge, MD, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date: May 30, 2025
Expiration Date: May 30, 2026